Growth Hormone Stimulation Tests in Children with Kabuki Syndrome

Dina A Schott1, Willem J M Gerver, Constance T R M Stumpel

  • 1Department of Paediatrics, Zuyderland Medical Centre, Heerlen, The Netherlands.

Insights

Growth hormone (GH) stimulation tests may not be reliable for assessing short stature in children with Kabuki syndrome. Insulin-like growth factor I (IGF-I) levels did not correlate with GH deficiency diagnosis.

Area of Science:

  • Pediatric Endocrinology
  • Genetics
  • Congenital Malformation Syndromes

Background:

  • Kabuki syndrome is a genetic disorder characterized by multiple congenital malformations.
  • Short stature is a common clinical feature in Kabuki syndrome, but its underlying cause is not well understood.

Purpose of the Study:

  • To investigate the utility of growth hormone (GH) stimulation tests in evaluating short stature in children with Kabuki syndrome.
  • To determine the correlation between GH stimulation peaks, insulin-like growth factor I (IGF-I), and IGF-binding protein 3 (IGFBP-3) levels in these patients.

Main Methods:

  • A prospective study evaluated 18 children (8 boys, 10 girls) with genetically confirmed Kabuki syndrome.
  • Two GH stimulation tests were performed, measuring serum IGF-I and IGFBP-3 levels.
  • GH stimulation peaks were analyzed in relation to age, sex, height, BMI, and IGF-I/IGFBP-3 SDS.

Main Results:

  • Five out of 18 children (27.8%) showed biochemical GH deficiency, not correlated with BMI SDS.
  • Only one patient had IGF-I below -2 SD, not meeting GH deficiency criteria.
  • Mean IGF-I levels were below normal (-0.8 SD), while IGFBP-3 levels were normal in all subjects.

Conclusions:

  • The diagnostic value of GH stimulation tests for assessing GH status in short stature associated with Kabuki syndrome is questionable.
  • IGF-I levels did not correlate with GH stimulation peaks or the diagnosis of GH deficiency in this cohort.
Abstract

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.0K
Nature and Nurture01:10

Nature and Nurture

Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience,...
22.6K
Signs of Puberty01:27

Signs of Puberty

Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
1.8K
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.1K